Tesaro (TSRO) PT Raised to $120 at Baird

October 10, 2016 7:51 AM EDT
Get Alerts TSRO Hot Sheet
Price: $74.96 --0%

Rating Summary:
    7 Buy, 19 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 13 | New: 20
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Baird analyst Michael Ulz reiterated an Outperform rating and raised his price target on Tesaro (NASDAQ: TSRO) to $120.00 (from $105.00) with full niraparib data better than expected.

Ulz commented, "Over the weekend, detailed data from the Phase 3 NOVA study of niraparib in 2L+ maintenance of ovarian cancer were presented at the ESMO meeting and published in the NEJM. Overall, the updated data further strengthens niraparib's market-leading position, supporting broad use across all platinum-sensitive patients with a manageable safety profile. Filing remains on track to complete in 4Q16, and we continue to anticipate approval in 1H17. We reiterate our Outperform rating and raise our price target to $120."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Robert W Baird